Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 2, 2008, Pages 207-215

  Rafiq, Nila ^a   Younossi, Zobair M ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Hepatitis C; NAFLD; NASH; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ALPHA TOCOPHEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; INTERLEUKIN 6; LEPTIN; METFORMIN; PEGINTERFERON ALPHA; RESISTIN; RIBAVIRIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID;

CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; FATTY LIVER; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOGENESIS; LIVER FIBROSIS; METABOLIC SYNDROME X; MIXED INFECTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; REVIEW; WEIGHT REDUCTION;

FATTY LIVER; HEPATITIS C, CHRONIC; HUMANS; METABOLIC SYNDROME X;

EID: 55649094639     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.2.207     Document Type: Review

References (42)

1. Ong J, Pitts A. Younossi ZM et al. The impact of nonalcoholic fatty liver disease (NAFLD) on mortality, a population-based cohort study. Hepatology 44(Suppl. 1), A660 (2006) (Abstract 660).
2. Cesario K, Khandwala F, Edwards K et al. Impact of obesity on degree of liver disease and response to therapy in patients with chronic hepatitis C virus infection. J. Hepatol. 42(Suppl. 2), 201-202 (2005) (Abstract).
3. Conjeevaram HS, Kleiner DE, Everhart JE et al. Race, insulin resistance and hepatic stearosis in chronic hepatitis C. Hepatology 45, 80-87 (2007).
4. Verma S, Bonacini M, Govindarajan S et al. More advanced hepatic fibrosis in Hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am. J. Gastroenterol. 101, 1817-1823 (2006).
5. Mehta SH, Brancati FL, Sulkowski MS, Stradthdee SA, Szklo M, Thomas DL. Prevalence of Type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann. Intern. Med. 133, 592-599 (2000).
6. Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 125, 1695-1704 (2003).
7. Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of Type 2 diabetes in a community-based longitudinal study. Am. J. Epidemiol. 166(2), 196-203 (2007).
8. Kawaguchi T, Ide T, Taniguchi E et al.. Clearance of HCV improves insulin resistance, β-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am. J. Gastroenterol. 102(3), 570-576 (2007).
9. Rubbia-Brandt L, Quadri R, Abid K et al.. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J. Hepatol. 33(1), 106-115 (2000).
10. Adinolfi LE, Gambardella M, Andreana A et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33(6), 1358-1364 (2001).
11. Rubbia-Brandt L, Giostra E, Mentha G et al. Expression of liver steatosis in hepatitis C virus infection and pattern of response to α-interferon. J. Hepatol. 35(2), 307 (2001).
12. Kumar D, Farrell GC, Fung C, George I. hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 36(5), 1266-1272 (2002).
13. Poynard T, Ratziu V, McHutchinson J et al. Effect of treatment with peginterferon or interferon α-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38(1), 75-85 (2003).
14. Shintani Y, Fujie H, Miyoshi H et al. hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126(3), 840-848 (2004).
15. Moriya K, Yotsuyanagi H, Shintani Y et al. hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J. Gen. Virology 78(Pt. 7), 1527-1531 (1997).
16. Kawaguchi T, Yoshida T, Harada M et al. hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am. J. Pathol. 165(5), 1499-1508 (2004).
17. Aytug S, Reich D, Sapiro LE et al. Impaired IRS-1/PI3-kinase signaling in patients, with HCV: a mechanism for increased prevalence of Type 2 diabetes. Hepatology 38(6), 1384-1392 (2003).
18. Pazienza V, Clement S, Pugnale P et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 45(5), 1164-1171 (2007).
19. Waris G, Felmlee DJ, Negro F et al. hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J. Virol. 81(15), 8122-8130 (2007).
20. Su AI, Pezacki JP, Wodicka L et al. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl Acad Sci. USA 99(24), 15669-15674 (2002).
21. Hottrioux C, Patient R, Morin A et al. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 56, 1302-1308 (2007).
22. Younossi Z, McCullough A, Ong J et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J. Clin. Gastroenterol. 38(8), 705-709 (2004).
23. Farroux L, Poujol-Robert A, Guechot J et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 54(7), 1003-1008 (2005).
24. Leandro G, Mangia A, Hui J et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130(6), 1636-1642 (2006).
25. Tarantino G, Conca P, Ariello M, Mastrolia M. Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis? Gut 55(5), 585-586 (2006).
26. Romero-Gomez M, Del Mar Viloria M, Andrade R et al. Insulin resistance impairs sustained response rate to peginterferon plus fibavirin in chronic hepatitis C patients. Gastroenterology 128(3), 636-641 (2005).
27. Westin J, Lagging M, Dhillon AP et al. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J. Viral Hepat. 14(10), 29-35 (2007).
28. Iacono O, Venezia G, Petta S et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 25(10), 1181-1191 (2007).
29. Bressler B, Wang K, Gries JM et al. Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEGylated interferon α2a. Hepatology 42(Suppl. 1), 661 (2005) (Abstract).
30. Walsh MJ, Jonsson JR, Richardson MM et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 55(4), 529-535 (2006).
31. Hickman IJ, Clouston AD, Macdonald GA et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 51(1), 89-94 (2002).
32. Hickman IJ, Jonsson JR, Prins JB et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvement in alanine aminotransferases, fasting insulin and quality of life. Gut 53 (3), 413-419 (2004).
33. Younossi ZM. Interactions between nonalcoholic fatty liver disease (NAFLD) and hepatitis C viral infection. J. Gastroenterol. Hepatol. 19 (Suppl. 7), S253-S257 (2004).
34. Charlton MR, Pockros P, Harrison S. The impact of obesity on treatment of chronic hepatitis C. Hepatology 43(6), 1177-1186 (2006).
35. Belfort R, Harrison SA, Brown K et al.. A placebo controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355(22), 2297-2307 (2006).
36. Kanatani Y, Usui I, Ishizuka K et al. Effects of pioglitazone on suppressor of cytokine signaling 3 expression. Potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes 56(3), 795-803 (2007).
37. Ikeda M, Abe K, Yamada M et al. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44(1), 117-125 (2006).
38. O'Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 45(4), 895-898 (2007).
39. Tanaka K, Kondo M, Sakaguchi T et al. Efficacy of ursodeoxycholic acid in combination with interferon-α in treating chronic hepatitis C: results of a long-term follow-up trial. J. Gastroenterol. Hepatol. 11(12), 1155-1160 (1996).
40. Lirussi F, Beccarello A, Bortolato L et al. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease. Liver 19(5), 381-388 (1999).
41. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-α-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 113(4), 1069-1073 (1997).
42. Look MP, Gerard A, Rao GS et al. Interferon/antioxidant combination therapy for chronic hepatitis C: a controlled pilot trial. Antiviral Res. 43(2), 113-122 (1999).